Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment.
作者： Stefanie Vincken , Sylvia Verbanck , Elke De Wachter , Eef Vanderhelst
DOI: 10.1183/13993003.02259-2018
关键词:
摘要: FeNOis low in stable adult patients with CF, and lower colonised P. aeruginosa. FeNOcannot be used as a noninvasive marker of CFTR function, since prolonged follow-up showed only transient rise FeNOafter starting ivacaftor.http://ow.ly/PtfC30ojYFc
sci-hub.se 参考文章(13)
Hartmut Grasemann, Tanja Gonska, Julie Avolio, Michelle Klingel, Elizabeth Tullis, Felix Ratjen, Effect of ivacaftor therapy on exhaled nitric oxide in patients with cystic fibrosis Journal of Cystic Fibrosis. ,vol. 14, pp. 727- 732 ,(2015) , 10.1016/J.JCF.2015.07.001
Kavitha Kotha, Rhonda D. Szczesniak, Anjaparavanda P. Naren, Matthew C. Fenchel, Leo L. Duan, Gary L. McPhail, John P. Clancy, Concentration of fractional excretion of nitric oxide (FENO): A potential airway biomarker of restored CFTR function. Journal of Cystic Fibrosis. ,vol. 14, pp. 733- 740 ,(2015) , 10.1016/J.JCF.2015.07.002
Claire E Wainwright, J Stuart Elborn, Bonnie W Ramsey, Gautham Marigowda, Xiaohong Huang, Marco Cipolli, Carla Colombo, Jane C Davies, Kris De Boeck, Patrick A Flume, Michael W Konstan, Susanna A McColley, Karen McCoy, Edward F McKone, Anne Munck, Felix Ratjen, Steven M Rowe, David Waltz, Michael P Boyle, None, Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR The New England Journal of Medicine. ,vol. 373, pp. 220- 231 ,(2015) , 10.1056/NEJMOA1409547
Karin M. de Winter-de Groot, Cornelis K. van der Ent, Nitric oxide in cystic fibrosis. Journal of Cystic Fibrosis. ,vol. 4, pp. 25- 29 ,(2005) , 10.1016/J.JCF.2005.05.008
LP Ho, JA Innes, AP Greening, None, Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. European Respiratory Journal. ,vol. 12, pp. 1290- 1294 ,(1998) , 10.1183/09031936.98.12061290
Hartmut Grasemann, Felix Ratjen, Cystic fibrosis lung disease: the role of nitric oxide. Pediatric Pulmonology. ,vol. 28, pp. 442- 448 ,(1999) , 10.1002/(SICI)1099-0496(199912)28:6<442::AID-PPUL10>3.0.CO;2-4
Nadzeya V. Marozkina, Benjamin Gaston, Nitrogen Chemistry and Lung Physiology Annual Review of Physiology. ,vol. 77, pp. 431- 452 ,(2015) , 10.1146/ANNUREV-PHYSIOL-021113-170352
Hartmut Grasemann, Karin Storm van's Gravesande, Rainer Büscher, Nicola Knauer, Eric S Silverman, Lyle J Palmer, Jeffrey M Drazen, Felix Ratjen, None, Endothelial Nitric Oxide Synthase Variants in Cystic Fibrosis Lung Disease American Journal of Respiratory and Critical Care Medicine. ,vol. 167, pp. 390- 394 ,(2003) , 10.1164/RCCM.200202-155OC
S. Dumcius, L. Hjelte, M. Proesmans, B. Tümmler, V. Vavrova, K. De Boeck, D. Bilton, G. Canny, S. Conway, Pulmonary exacerbation: towards a definition for use in clinical trials. Report from the EuroCareCF Working Group on outcome parameters in clinical trials. Journal of Cystic Fibrosis. ,vol. 10, ,(2011) , 10.1016/S1569-1993(11)60012-X
C. Keen, P. Gustafsson, A. Lindblad, G. Wennergren, A-C. Olin, Low levels of exhaled nitric oxide are associated with impaired lung function in cystic fibrosis. Pediatric Pulmonology. ,vol. 45, pp. 241- 248 ,(2010) , 10.1002/PPUL.21137